Accumulation of myeloid-derived suppressor cells (MDSCs) associated with inhibition of dendritic cell (DC) differentiation is one of the major immunological abnormalities in cancer and leads to suppression of antitumor immune responses. The molecular mechanism of this phenomenon remains unclear. We report here that STAT3-inducible up-regulation of the myeloid-related protein S100A9 enhances MDSC production in cancer. Mice lacking this protein mounted potent antitumor immune responses and rejected implanted tumors. This effect was reversed by administration of wild-type MDSCs from tumor-bearing mice to S100A9-null mice. Overexpression of S100A9 in cultured embryonic stem cells or transgenic mice inhibited the differentiation of DCs and macrophages and induced accumulation of MDSCs. This study demonstrates that tumor-induced up-regulation of S100A9 protein is critically important for accumulation of MDSCs and reveals a novel molecular mechanism of immunological abnormalities in cancer.
Defective myeloid cell diff erentiation is one of the major factors underlying the immune nonresponsiveness of both solid tumors and hematological malignancies ( 1 ) . Consequences of defective myeloid cell diff erentiation include decreased production of mature, functionally competent DCs and accumulation of myeloidderived suppressor cells (MDSCs) ( 2 -4 ) . MDSCs are a mixed group of myeloid cells including immature granulocytes, macrophages, DCs, and myeloid progenitors. In mice, MDSCs with the phenotype of Gr-1 + CD11b + cells were detected in practically all tested tumor models. Signifi cant accumulation of these cells was found in patients with various types of cancer ( 5 -9 ) . Numerous studies have demonstrated a critical role of MDSCs in the suppression of T cell responses and induction of T cell tolerance in cancer ( 10 -13 ) . MDSCs may account in large part for the limited eff ectiveness of cancer vaccines and other therapies such as anti -vascular endothelial growth factor (VEGF) treatment ( 8, 14, 15 ) . Recent studies have also demonstrated an important function of these cells in infection, infl ammation, and prevention of graft rejection ( 16 -20 ) .
Despite the wealth of information regarding the functional importance of MDSCs, the mechanism responsible for their accumulation remains unknown. Various tumor-derived factors (VEGF, IL-6, IL-10, M-CSF, and GM-CSF) can inhibit DC diff erentiation from hematopoietic progenitor cells (HPCs) in vitro and in vivo ( 1 ) . In search of specifi c genes responsible for abnormal myeloid cell diff erentiation in cancer, we evaluated the eff ect of VEGF on HPC gene expression by diff erential display analysis and consistently found up-regulation of the mouse S100A9 gene. S100A9, also referred to as myeloid-related protein 14 (MRP14) or CORRESPONDENCE Dmitry Gabrilovich: dmitry.gabrilovich@moffi tt.org Abbreviations used: ChIP, chromatin immunoprecipitation assay; EB, embryoid body; ES, embryonic stem; FCM, fi broblast-conditioned medium; HPC, hematopoietic progenitor cell; IMC, immature myeloid cell; LIF, leukemia inhibitory factor; MDSC, myeloid-derived suppressor cell; ROS, reactive oxygen species; SCF, stem cell factor; TCM, tumor cell -conditioned medium; TLR, Toll-like receptor; VEGF, vascular endothelial growth factor.
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Inhibition of dendritic cell diff erentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein
calgranulin B, is a member of the large family of S100 proteins. It is expressed together with its dimerization partner S100A8 (MRP8 or calgranulin A) in circulating neutrophils and monocytes, but not in resting tissue macrophages ( 21 ) . S100A9 protein contains two helix -loop -helix motifs (EFhand), which have high affi nity for Ca 2+ ( 22 ) . Upon elevation of intracellular calcium, S100A8 and S100A9 translocate from the cytosol to the cytoskeleton and the plasma membrane of myeloid cells ( 23 ) and are released as a heterodimer to recruit leukocytes to sites of infl ammation or tumors ( 24 ) . Until now, their role in myeloid cell diff erentiation remained unknown. We report here that up-regulation of S100A9 in myeloid precursors in cancer inhibits DC and macrophage diff erentiation and induces accumulation of MDSCs. This may represent a universal molecular mechanism of tumor-induced abnormalities in myeloid cells in cancer, directly linking infl ammation and immune suppression. S100A9 and S100A8 mRNAs and proteins were readily detectable in enriched bone marrow HPCs, but gradually decreased during culture with GM-CSF and IL-4 and were almost undetectable by day 7, when > 70% of cells in culture were DCs ( Fig. 1 A and Fig. S1 , A and B, available at http:// www.jem.org/cgi/content/full/jem.20080132/DC1). Thus, under physiological conditions, DC diff erentiation was associated with marked down-regulation of S100A8 and S100A9. To evaluate the eff ect of tumor-derived factors on S100A9 expression, HPCs were cultured for 7 d with GM-CSF and IL-4 in CT-26 tumor cell -conditioned medium (TCM) or 3T3 fi broblast-conditioned medium (FCM). TCM prevented the down-regulation of S100A9 mRNA expression during diff erentiation in vitro ( Fig. 1 A ) . Previous studies have shown that in contrast to FCM, TCM inhibits the diff erentiation of DCs from HPCs and induces the accumulation of Gr-1 + CD11b + MDSCs ( 25 -27 ) . To verify the suppressive activity of these MDSCs, HPCs were cultured for 5 d with GM-CSF, IL-4, and TCM. Consistent with previous results, TCM substantially decreased the proportion of CD11c + DCs and increased the proportion of Gr-1 + CD11b + MDSCs (Fig. S2 ). Gr-1 + CD11b + cells were then sorted and added to splenocytes from C57BL/6 mice stimulated with anti-CD3/CD28 antibody or to OT-1 splenocytes (CD8 + T cells from these mice have a TCR that recognizes the OVA-derived peptide SIINFEKL) stimulated with control or specifi c peptide. Gr-1 + CD11b + cells generated in TCM signifi cantly suppressed T cell responses ( Fig. 1 B ) .
RESULTS

S100A9 expression is associated with accumulation of MDSCs in cancer
We asked whether the observed up-regulation of S100A8 and S100A9 by TCM was associated with MDSC accumulation. Gr-1 + cells isolated after a 5-d culture of HPCs with GM-CSF and IL-4 in TCM expressed substantially more S100A8 and S100A9 proteins than did Gr-1 Ϫ cells ( Fig. 1 C ) . No diff erences in the levels of S100A8 and S100A9 were found between Gr-1 + cells isolated from populations cultured with FCM versus TCM. RNA was extracted on days 0, 1, 3, and 7, and qRT-PCR was performed. The level of expression of S100A9 was normalized to 18S rRNA. Two experiments yielded the same results. (B) HPCs from naive C57BL/6 mice were cultured for 5 d with GM-CSF and IL-4 in complete medium alone (control) or conditioned media from EL-4 cells (TCM). Gr-1 + cells were isolated at the end of 5-d culture and added at 1:4 ratio to splenocytes from OT-1 mice. The number of IFN-␥ -producing cells in response to stimulation by the specifi c or control peptides was evaluated in an ELISPOT assay and calculated per 2 × 10 5 splenocytes. S.P. represents the number of spots in cells stimulated with control peptide subtracted from the number of spots in cells stimulated with specifi c peptide. In parallel, Gr-1 + cells were added at 1:4 ratio to splenocytes from naive C57BL/6 mice and stimulated with 0.5 μ g/ml anti-CD3 and 5 μ g/ml anti-CD28 antibodies. The number of IFN-␥ cells was evaluated in ELISPOT assay. Two experiments were performed. * represents the statistically signifi cant (P < 0.05) differences between control and TCM groups. (C) HPCs from C57BL/6 mice were cultured for 5 d with GM-CSF and IL-4 in the presence of conditioned media (25% vol/vol) from NIH 3T3 fi broblasts (NIH 3T3) or C3 fi brosarcoma cells (C3). Gr-1 + or Gr-1 Ϫ cells were isolated using magnetic beads by two rounds of isolation. Proteins extracted from cells were subjected to Western blotting using indicated antibodies. Two experiments with the same results were performed. (D) Expression of S100A8 and A9 proteins in whole cell lysates of splenocytes from CT26 tumor-bearing mice. N, naive tumor-free mice. (E) Gr-1 + and Gr-1 Ϫ cells were isolated from spleens of naive mice (control) or mice bearing 3-wk-old CT26 tumor (tumor) as described above. The levels of proteins were evaluated by Western blotting. Two experiments with the same results were performed.
The correlation between MDSC accumulation and S100A8/A9 levels was investigated in CT26 colon carcinoma-bearing mice. Consistent with previous observations ( 28, 29 ) , the proportion of MDSCs in the spleens of these diff erences were found in the proportions of the populations of myeloid cells in spleens (Fig. S3 A, available at http:// www.jem.org/cgi/content/full/jem.20080132/DC1), blood, and bone marrow (not depicted) between wild-type and S100A9KO mice. Likewise, no signifi cant diff erences in the presence of the myeloid populations were observed after in vitro diff erentiation of HPCs (Fig. S3 B) .
To evaluate diff erentiation of myeloid cells in the presence of tumor-derived factors, enriched HPCs isolated from S100A9KO mice and their wild-type littermates were cultured with GM-CSF for 5 d in TCM. Consistent with previous observations (for review see [ 1 ] ), tumor-derived factors signifi cantly reduced the diff erentiation of DCs and macrophages and substantially increased the production of Gr-1 + CD11b + MDSCs in wild-type populations. In contrast, TCM did not appreciably inhibit the diff erentiation of myeloid cells from S100A9KO mice ( Fig. 2 A ) . Thus, loss of mice increased gradually during tumor growth, and by 3 wk after inoculation was more than fi vefold higher than in the spleens of control mice (unpublished data). Amounts of S100A8 and S100A9 increased in spleens of tumor-bearing mice in parallel with MDSC accumulation ( Fig. 1 D ) . Similar to the in vitro experiments, S100A8/A9 proteins were detected in the Gr-1 + , but not the Gr-1 Ϫ population, and no diff erences in protein levels were noted between Gr-1 + cells from naive and tumor-bearing mice ( Fig. 1 E ) . Thus, the increased expression of S100A8 and S100A9 in spleens of tumor-bearing mice and the TCM-inducible up-regulation of S100A8 and S100A9 in vitro are associated exclusively with the accumulation of MDSCs.
S100A9 is essential for MDSC accumulation in cancer
To determine whether MDSC accumulation requires S100A9, we examined S100A9-defi cient (S100A9KO) mice ( 32 ) . No Figure 2 . Lack of S100A9 affects generation of MDSCs under pathological conditions. (A) Enriched HPCs were isolated from bone marrow of S100A9 KO mice (KO) and their wild-type littermates (WT). Cells were cultured with GM-CSF and IL-4 for 5 d in complete culture medium or in the presence of EL-4 TCM. The cell phenotypes were evaluated by fl ow cytometry. Mean ± SD of the proportions of indicated cell populations from three mice are shown. (B) EL-4 cells (3 × 10 5 ) were injected s.c. into wild-type (WT) or S100A9 knockout (KO) mice and tumor size was measured. Anti-CD8 antibody (200 μ g) was injected i.p. into KO mice 3 and 1 d before injection of tumor cells. The S100A9KO group included 12 mice, WT group 15 mice, and KO mice treated with anti-CD8 antibody 5 mice. Tumor size for each mouse is shown. (C) Phenotypes of splenocytes from wild-type (S100A9 +/+ ) and knockout (S100A9 Ϫ / Ϫ ) mice 15 d after EL-4 cell injection were evaluated using multicolor fl ow cytometry. * represents statistically signifi cant differences between the groups (P < 0.05). (D) Wild-type and S100A9 knockout mice were injected s.c. with 200 μ l of CFA. The presence of Gr-1 + CD11b + cells was monitored in peripheral blood. Each group included 4 mice. Mean ± SD are shown. (E) Gr-1 + CD11b + cells in spleens of wild-type and S100A9 knockout mice on day 12 after CFA injection. Four mice per genotype were analyzed. * represents statistically signifi cant differences between the groups (P < 0.05). (F) S100A9 Ϫ / Ϫ mice were injected s.c. with 2 × 10 5 EL-4 tumor cells and then split into 2 groups of 5 mice. One group was left untreated (no transfer) and the other group was treated i.v. with 3 × 10 6 Gr-1 + CD11b + cells isolated from tumor-bearing wild-type mice (MDSC) on days 1, 3, 5, and 7 after tumor inoculation. Tumor size for each mouse is shown.
CFA induced a more than fi vefold increase in the proportion of circulating MDSCs in wild-type mice, which peaked on days 6 -9 after injection and returned to control level by day 13. In contrast, the number of circulating MDSCs did not increase in S100A9KO mice at any time point ( Fig. 2 D ) . A similar pattern was observed in spleens on day 13 after CFA injection ( Fig. 2 E ) . Thus, the absence of S100A9 protein prevents accumulation of MDSCs in response to CFA, as well as to tumor challenge.
To address the potential contribution of MDSC accumulation to tumor rejection, we performed adoptive transfers of MDSCs. S100A9KO mice were injected with EL-4 lymphoma cells, and then split into two groups of fi ve mice each. One group was untreated and the other group was injected with MDSCs isolated from EL-4 tumor-bearing wild-type mice. 4 out of 5 untreated S100A9KO mice rejected their tumors by day 17, whereas all 5 S100A9KO mice injected with MDSCs developed rapidly growing tumors ( Fig. 2 F ) . Collectively, these results suggest that the absence of MDSC accumulation in S100A9 KO mice is responsible for their ability to reject tumors.
S100A9 overexpression impairs differentiation of DCs and induces accumulation of MDSCs
We asked whether overexpression of S100A9 and A8 could directly regulate the diff erentiation of DCs and other myeloid cells. To address this question, we generated stable clones of R1 embryonic stem (ES) cells that overexpress S100A8, S100A9, or both (S100A8/9). R1 ES cells transfected with empty vector or another member of S100 family, S100A1, served as controls. Cells were subjected to in vitro diff erentiation of DCs, as previously described ( 33 ) . The expression of S100A8 and S100A9 was verifi ed by qRT-PCR, as well as by Western blotting ( Figs. 3, A and B ) . Endogenous S100A8 and S100A9 genes were expressed in the control ES cells, but were shut down in embryoid bodies (EBs). The expression of these genes in transfected ES cells was continuously maintained during cell culture (Fig. S7 , available at http://www .jem.org/cgi/content/full/jem.20080132/DC1).
On day 35 after the start of the cultures, cells generated from EBs were collected to evaluate their phenotype by fl ow cytometry. The total numbers of these cells were similar in all groups (unpublished data). More than 80% of cells generated from control-or S100A1 -transfected ES cells had a phenotype of mature DCs (CD11c + IA b+ or CD11c + B7-2 + ; Fig. 3 C ) . In sharp contrast, ES cells transfected with S100A9 or S100A8/A9 displayed a dramatically reduced ability to generate DCs. Instead of DCs, these ES cells produced predominantly Gr-1 + cells. The eff ect of S100A8 on DC diff erentiation was similar, although much less pronounced. S100A8 did not increase the level of Gr-1 + CD11b + cells ( Fig. 3 C ) . Reduced DC generation from S100A8/ 9-transfected ES cells was verifi ed in a functional test using the allogeneic mixed leukocyte reaction, a hallmark of DC activity. Cells diff erentiated from S100A8/9 ES cells had a much lower ability to stimulate the proliferation of S100A9 prevents the defective diff erentiation of TCMtreated myeloid cells.
To evaluate the eff ect of S100A9 defi ciency on tumor growth, control and S100A9KO mice were injected s.c. with 5 × 10 5 EL-4 lymphoma cells. By days 8 -10 after inoculation, tumor growth was evident in all mice ( Fig. 2 B ) . Tumors continued to grow aggressively in all 15 wild-type mice. In sharp contrast, tumors were rejected in 9 out of 12 S100A9KO mice (P = 0.0002). Mean tumor size in the remaining three S100A9KO mice was signifi cantly smaller than in the wild-type mice (238.7 ± 51.8 vs. 521.5 ± 199.3, P = 0.008). Similar results were obtained in the C3 sarcoma tumor model (Fig. S4 , available at http://www.jem .org/cgi/content/full/jem.20080132/DC1).
To investigate whether immunological mechanisms were involved in tumor rejection, S100A9KO mice were injected i.p. with 200 μ g of anti-CD8 antibody 3 d and 1 d before tumor injection. This treatment reduced the level of CD8 + T cells in peripheral blood by more than fi vefold (unpublished data). None of the S100A9KO mice treated with anti-CD8 antibody rejected their tumors. Tumor growth in these mice was similar to that in S100A9 wild-type mice ( Fig. 2 B ) . Splenocytes were obtained from S100A9KO and wild-type littermates 12 -13 d after injection of EL-4 cells and restimulated for 6 d with irradiated EL-4 tumor cells. T cells were collected and used as eff ectors in cytotoxicity assays against either EL-4 cells, unrelated B16 melanoma cells, or peritoneal macrophages obtained from naive C57BL/6 mice. T cells from S100A9KO mice showed substantially higher cytotoxicity against EL-4 cells than did T cells from wild-type mice. However, no diff erences were found in cytotoxicity against macrophages or B16 cells (Fig. S5 , available at http:// www.jem.org/cgi/content/full/jem.20080132/DC1). Tumors removed from wild-type mice 12 d after tumor cell injection had clearly visible infi ltration of S100A9 + cells and Gr-1 + cells, whereas these cells were absent from tumors from S100A9KO mice (Fig. S6 , A and B). Tumors from S100A9 KO mice had visible infi ltration of CD8 + and CD4 + T cells, which was absent in tumor from S100A9 wild-type mice (Fig. S6 , C and D) Tumors from S100A9 wild-type mice had viable cells and infi ltrated adjacent adipose tissue. In contrast, tumors from S100A9KO mice had extensive necrosis and apoptosis at the periphery (Fig. S6 E) . By day 15 after tumor cell injection, tumor-bearing wild-type mice expressed substantially more Gr-1 + CD11b + MDSCs than did tumorfree mice (11% in Fig. 2 C vs. 4% in Fig. 2 A ) . In contrast, the proportion of these cells in tumor-bearing S100A9KO mice was the same as in tumor-free S100A9KO mice and signifi cantly (P < 0.05) lower than in tumor-bearing wildtype mice ( Fig. 2 C ) . Thus, MDSCs do not accumulate in tumors in the absence of S100A9.
To address the need for S100A9 for MDSC generation in a tumor-independent model, we injected mice with CFA to mimic the conditions of infection and infl ammation, which are known to stimulate production of MDSCs. The level of MDSCs was monitored in peripheral blood by fl ow cytometry. onstrated high-level expression of targeted cDNA in hematopoietic cells from spleens, lymph nodes, and thymus ( 34 ), as well as in HPCs and stem cells in bone marrow ( 35 ) . To better trace the expression of the transgene transcript, GFP was linked to the S100A9 cDNA behind an IRES sequence to permit independent translation ( Fig. 4 A ) . FVB/N mice derived from the zygotes injected with this H2K-S100A9-GFP transgenic construct were genotyped by slot blot hybridization to a GFP probe and phenotyped by FACS analysis for GFP expression in peripheral blood cells. Nine founder mice stably integrated the transgene. Expression of GFP protein in peripheral blood cells was signifi cant in one founder mouse ( Fig. 4 B , left) . Transgene-positive off spring from this founder line exhibited a consistent level of GFP expression during breeding for several generations to wild-type mice. The level of GFP expression was stable during the lifetime of these mice for at least 32 wk (the period of observation). The level of S100A9 protein in spleens obtained from allogeneic T cells than did cells diff erentiated from control ES cells ( Fig. 3 D ) . S100A9-, A8-, or 8/9 -transfected progeny did not express CD34 or Sca-1 markers. However, more than half of these cells expressed c-kit ( Fig. 4 E ) , suggesting that S100A8/9 might cause accumulation of myeloid progenitor cells. This hypothesis was tested in a colony formation assay. Cells diff erentiated from control ES cells did not form colonies, whereas a signifi cant number of colonies were formed by cells diff erentiated from S100A9 or S100A8/9 ES cells ( Figs. 3 F ) . Most of the colonies morphologically resembled granulocytemacrophage CFU-GMs (Fig. S8 , available at http://www.jem .org/cgi/content/full/jem.20080132/DC1).
To investigate the role of S100A9 in myeloid cell diff erentiation in vivo, we generated transgenic mice (S100A9Tg) that overexpress S100A9 in hematopoietic cells under control of the H2K-promoter/enhancer and Moloney MuLV enhancer/poly(A) site ( 34 ) . This promoter previously dem- Figure 3 . Effect of S100A9 overexpression on DC differentiation from ES cells. ES cells were transfected with empty vector (vector), S100A1, S100A8, S100A9, or a combination of S100A8 and 9 (S100A8/9). (A) Expression of S100A8 and A9 was evaluated in transfected ES cells using qRT-PCR. (B) Western blot assay for S100A9 and A8 in ES cells transfected with pcDNA-S100A9 and pcDNA-S100A8. Lane 1, empty vector; lane 2, S100A8; lane 3, S100A9; and lane 4, S100A8/9. (C) Phenotypes of cells generated from ES cells cultured for 35 d using the combination of cytokines described in Materials and methods. Expression of different surface molecules was evaluated by fl ow cytometry. Mean and SD from four different experiments are shown. (D) Effector T cells were isolated from allogeneic BALB/c mice and 10 5 cells per well were mixed in triplicates of U-bottomed 96-well plates with different numbers of irradiated cells generated from ES cells. Vector, ES cells transfected with empty vector; S100A8/9, ES cells transfected with S100A8 and A9. Two different clones (#6 and #7) of ES cells are shown. HPC-DC, DCs generated from bone marrow progenitor cells by 5-d culture with GM-CSF and IL-4. T cell proliferation was measured by 3 [H]thymidine uptake and expressed as counts per minute (CPM). Three experiments were performed. Mean ± SD is shown. T cells alone showed < 500 CPM count (not depicted). (E and F) Cells were generated from ES cells and either used for analysis of phenotype by fl ow cytometry (E) or for colony formation in semisolid medium supporting the growth of myeloid colonies (StemCell Technologies). (F) Colony formation was evaluated in duplicates, and the number of colonies was calculated per 10 5 cells.
cells were sorted from S100A9Tg mice ( Fig. 4 C ) . HPCs were cultured for 5 d with a cocktail of cytokines (Flt3, stem cell factor [SCF], IL-11, GM-CSF, and IL-3), followed by a 7-d incubation with GM-CSF; LPS was present in the culture medium for the last 24 h. As shown in Fig. 4 D , the cells generated from wild-type HPCs were CD11c + IA q+ DCs transgenic mice was substantially higher than in wild-type mice ( Fig. 4 B , right) .
To investigate the eff ect of S100A9 on the diff erentiation of myeloid cells, we isolated lineage-negative, c-kit -positive HPCs from bone marrow of control (wild-type) FVB/N mice and S100A9Tg mice. Lin Ϫ c-kit + GFP Ϫ and Lin Ϫ c-kit + GFP + from naive FVB/N mice were stimulated with allogeneic DCs from BALB/c mice in the presence of IMCs. IMCs from S100A9Tg, but not wild-type mice, signifi cantly suppressed T cell proliferation at 1:2 and 1:4 ratios ( Fig. 5 F ) .
To assess possible eff ects of S100A9 overexpression on tumor growth, wild-type and S100A9Tg mice were injected s.c. with 5 × 10 5 AVN tumor cells. AVN cells were established from a spontaneous, relatively immunogenic, slowgrowing tumor arising in FVB/N MMTV-Neu Tg mice ( 36 ) . Injection of tumor cells into S100A9Tg mice resulted in rapid tumor growth ( Fig. 5 G ) . Tumors were clearly detectable in all S100A9Tg mice by week 2 and were > 200 mm 2 in size 1 wk later (mean size 286.5 ± 153.9 mm 2 ). In contrast, only a few tumors were visible by week 2 in wild-type mice. By day 25, the mean tumor size of wild-type mice was only 84.6 ± 71.9 mm 2 (P = 0.001).
STAT3 regulates expression of S100A9
Previous studies have shown that the eff ect of tumors on DCs and MDSCs is mediated via hyperactivation of the Jak2 -STAT3 pathway, which is triggered by most of the tumor-derived factors implicated in abnormal myeloid cell diff erentiation in cancer ( 27, 30 ) . The promoter regions of S100A8 and S100A9 contain several potential STAT3 binding sites (TTCCC G/A G/T AA). In chromatin immunoprecipitation assays of 32D myeloid cells, STAT3 interacted with the promoter regions of both S100A8 and S100A9 ( Fig. 6 A ) . Thus, it is possible that STAT3 regulates the transcription of S100A8 and S100A9 .
In support of this hypothesis, ES cells cultured in the presence of leukemia inhibitory factor (LIF) displayed functionally active phospho-STAT3 and high S100A9 mRNA expression, whereas LIF withdrawal substantially reduced amounts of both pY 705 STAT3 and S100A9 mRNA within 48 h ( Fig. 6 , B and C ). Expression of the constitutively active STAT3 mutant STAT3C in ES cells maintained a high level of S100A9 expression after LIF withdrawal ( Fig. 6, B and C ) .
To examine the role of STAT3 in the regulation of S100A9 expression in vivo , we used Mx1-Cre/STAT3 loxP bitransgenic mice, which have an inducible deletion of the STAT3 gene ( 31 ) . In these mice, ablation of STAT3 in hematopoietic cells is achieved after injection of poly(I:C). STAT3 loxP/loxP mice (without Mx1-Cre) were used as controls. Splenocytes were collected 10 d after injection of poly(I:C). Poly(I:C) treatment substantially reduced amounts of STAT3 and S100A8/A9 in both Gr-1 + and Gr-1 Ϫ cells of Mx1-Cre/ Stat3 loxP mice, but not of control mice ( Fig. 6 D ) .
Finally, we depleted STAT3 from 32D cells by RNA interference. 32D cells were transfected with either control siRNA or STAT3 siRNA, and down-regulation of STAT3 by STAT3 siRNA was confi rmed by Western blotting ( Fig. 6 F ) . STAT3 depletion resulted in the down-regulation of S100A8 and S100A9 gene expression ( Fig. 6 E ) , as well as the levels of both proteins ( Fig. 6 F ) . Collectively, these data demonstrate that STAT3 up-regulates the expression of S100A8 and S100A9 both in vitro and in vivo.
(20%), F4/80 + Gr-1 Ϫ macrophages (30%), and Gr-1 + CD11b + immature myeloid cells (IMCs; 35%). No statistically significant diff erences were found between the percentages of cell types generated from wild-type HPCs and GFP Ϫ HPCs from S100A9Tg mice. GFP + HPCs from S100A9Tg mice produced few DCs and macrophages, whereas > 50% of the total cell population consisted of Gr-1 + CD11b + IMCs ( Fig. 4 D ) . In contrast to cells generated from wild-type and GFP Ϫ transgenic HPCs, cells generated from GFP + transgenic HPCs failed to stimulate allogeneic T cells ( Fig. 4 E ) , confi rming the very low presence of DCs.
The total number of GFP Ϫ Gr-1 + CD11b + IMCs in S100A9Tg mice was the same as in wild-type mice. In contrast, the number of GFP + IMCs was fi vefold higher than in wild-type mice. Although the total number of GFP + IMC cells decreased in older mice, the diff erence between S100A9Tg and wild-type mice was maintained ( Fig. 5 A ) . The proportions of DCs and macrophages were evaluated in spleens of 3-wk-old wild-type and S100A9Tg mice. In S100A9Tg mice, GFP + and GFP Ϫ populations were analyzed separately. No diff erences were found in the proportions of DCs and macrophages between splenocytes from wild-type mice and GFP Ϫ splenocytes from S100A9Tg mice. In the population of GFP + splenocytes, the percentages of DCs and macrophages were signifi cantly lower than in GFP Ϫ splenocytes ( Fig. 5 B ) . Next, we evaluated the level of myeloid precursors in wild-type and S100A9Tg mice. Percentages of c-kit + cells in bone marrow were sixfold higher in GFP + populations of S100A9Tg mice than in either GFP Ϫ populations or wildtype mice ( Fig. 5 C ) . Diff erences in c-kit expression in spleens were less dramatic but statistically signifi cant (P < 0.05; unpublished data). The ability of bone marrow cells and splenocytes from S100A9Tg mice to form myeloid colonies was signifi cantly (P < 0.05) greater than that of cells from wild-type mice ( Fig. 5 D and Fig. S9 , available at http://www.jem.org/cgi/content/full/jem.20080132/DC1). Collectively, these data indicate that overexpression of S100A9 in hematopoietic cells results in accumulation of myeloid progenitors and IMC at the expense of DC and macrophage diff erentiation.
To evaluate the possible immunosuppressive activity of IMCs generated in S100A9Tg mice, Gr-1 + CD11b + cells were sorted from wild-type and transgenic tumor-free mice. Two experimental systems were used: peptide-specifi c CD8 + T cell response and allogenic mixed leukocyte reaction. In the fi rst experimental system, peptide-specifi c CD8 + T cells were generated by immunizing naive FVB/N mice with DCs loaded with MHC class I (H2-D q ) -restricted rat HER-2/ neu -derived peptide PDSLRDLSVF. Splenocytes were isolated and stimulated with control or specifi c peptide in the presence of IMCs. The number of IFN-␥ -producing cells was evaluated by ELISPOT assay. IMCs from S100A9Tg mice signifi cantly reduced the number of antigen-specifi c CD8 + T cells, whereas IMCs from wild-type mice did not ( Fig. 5 E ) . In the second experimental system, T cells isolated independent assays were performed. First, splenocytes (10 6 /ml) from control and S100A9Tg mice were cultured for 48 h, and extracellular levels of S100A8 and S100A9 proteins were measured by ELISA. The concentrations of the proteins were similar in both groups ( ‫ف‬ 150 ng/ml).
S100A9 regulates myeloid cell differentiation via reactive oxygen species (ROS)
It is possible that overexpression of S100A9 in myeloid cells results in increased secretion of the protein, which in turn inhibits HPC diff erentiation. To investigate this possibility, three In transgenic mice, the proportion of cells was calculated separately for GFP + and GFP Ϫ cells. Each group included three mice. Mean ± SD. * represents statistically signifi cant differences between GFP + and GFP Ϫ cells (P < 0.05). (D) Colony formation assay of splenocytes and bone marrow cells isolated from wild-type or S100A9Tg mice. Total myeloid colonies were calculated per 2 × 10 5 cells in spleen and per 2 × 10 4 cells in bone marrow. * represents statistically signifi cant differences between WT and Tg mice (P < 0.05). (E) Gr-1 + CD11b + IMC were sorted from spleens of wild-type (WT) or S100A9Tg mice (Tg) and added at a 1:3 or 1:6 ratio to splenocytes from FVB/N mice immunized with specifi c MHC class I -restricted PDSLRDLSVF peptide. Cells were stimulated with control (RAHYNIVTF) or specifi c peptides, and the number of IFN-␥ -producing cells was evaluated in quadruplicates in ELISPOT assay. The numbers of spots in cells stimulated with control peptide were subtracted from values in cells stimulated with specifi c peptide. Mean ± SD from three experiments are shown. * represents statistically signifi cant differences from splenocytes cultured without IMC (P < 0.05). (F) Gr-1 + CD11b + IMCs were sorted from WT or S100A9Tg mice (Tg). In transgenic mice, these cells were separated into GFP + and GFP Ϫ cells. T cells were isolated from naive FVB/N mice and DCs were generated from bone marrow of naive BALB/c mice. DCs were mixed with T cells at 1:50 ratio and IMC were added at the indicated ratio. Cells were cultured in triplicates in round-bottomed 96-well plates for 4 d. 3 [H]thymidine uptake was measured. Mean ± SD from three experiments are shown. * represents statistically signifi cant differences from splenocytes cultured without IMC (P < 0.05). (G) AVN cells (5 × 10 5 ) were injected s.c. into wild-type or S100A9Tg mice and tumor size was monitored. Each group included six mice.
Gr-1 + GFP + cells from S100A9Tg mice than in Gr-1 + GFP Ϫ cells from wild-type and S100A9T mice ( Fig. 7 A ) .
We determined whether tumor burden aff ected ROS levels in MDSCs in S100A9KO mice. EL-4 tumors were established in wild-type and S100A9KO mice, and ROS levels were evaluated in Gr-1 + CD11b + MDSCs in spleens at a time when all mice had similar tumor sizes (12 d after tumor inoculation). Consistent with previous reports, MDSCs from wild-type, tumor-bearing mice produced substantially more ROS than did Gr-1 + CD11b + IMCs from naive mice and ( Fig. 7 B ) . ROS levels in IMCs from naive S100A9KO mice were only slightly lower than in IMCs from wild-type mice. However, ROS levels in MDSCs from tumor-bearing S100A9KO mice were substantially lower than in tumorbearing wild-type mice and were equivalent to ROS levels in naive wild-type mice ( Fig. 7 B ) .
We asked whether ROS aff ected the diff erentiation of MDSCs from tumor-bearing mice. EL-4 tumors were established in wild-type and gp91 Ϫ / Ϫ mice, which lack a critical component of the NADPH complex and produce very little ROS. MDSCs (90 -95% pure) were isolated from spleens 3 wk after tumor inoculation and cultured in the presence of GM-CSF and TCM for 7 d. MDSCs from tumor-bearing wild-type and gp91 Ϫ / Ϫ mice expressed S100A9 ( Fig. 7 C , inset) . However, the lack of ROS in gp91 Ϫ / Ϫ mice dramatically enhanced MDSC diff erentiation. Despite the presence of S100A9, < 5% of gp91 Ϫ / Ϫ cells retained an immature phenotype (Gr-1 + CD11b + ) after 7 d in culture, compared with Second, Lin Ϫ c-kit + myeloid progenitors derived from the bone marrow of naive FVB/N mice were placed in the bottom chambers of 24-well Transwell plates. Splenocytes (1.5 × 10 6 cells per ml) from wild-type or S100A9Tg mice were placed in the top chambers (which are separated from the bottom chambers by a semipermeable membrane) and were cultured with a cocktail of cytokines supporting myeloid differentiation. Splenocytes in the top chambers were replaced every 3 d. The progenitor cells diff erentiated into mature myeloid cells regardless of whether the splenocytes in the top chambers overexpressed S100A9 or not (unpublished data).
Third, Lin Ϫ c-kit + progenitors were cultured in the presence of diff erent concentrations of recombinant S100A8, S100A9, or S100A8/A9 heterodimer. None of these proteins at concentrations of 1 or 5 μ g/ml signifi cantly reduced the proportion of mature myeloid cells generated from myeloid progenitors. Collectively, the results suggest that overexpression of S100A9 inhibits myeloid diff erentiation primarily via intracellular mechanisms.
We and others have previously shown that one of the main characteristics of MDSCs from tumor-bearing mice is high production of ROS ( 28, 29, 37 ) . Recent studies have implicated S100A9 protein in the regulation of ROS generation by NAPDH oxidase ( 23, 38 -41 ) . We hypothesized that tumor-induced up-regulation of S100A9 in progenitors might inhibit myeloid diff erentiation by increasing production of ROS. Consistent with this hypothesis, amounts of ROS in the spleen and bone marrow were four-to fi vefold greater in injections of 100 μ g poly(I:C) 7 d apart. Undeleted STAT3 loxP/loxP mice were used as a control. Gr-1 + and Gr-1 Ϫ cells were isolated from spleens of control (STAT3 +) and STAT3 defi cient mice (STAT3 -), and the levels of STAT3, S100A8, and S100A9 proteins were evaluated by Western blotting. Two experiments with the same results were performed. (E and F) 32D cells were transfected with STAT3 siRNA. As a control, nontargeting siRNA pool was used (siGenome). (E) Expression of S100A8 and A9 mRNA was measured in quadruplicates by qPCR. Mean ± SD are shown. * represents statistically signifi cant difference from control (P < 0.05). (F) The level of indicated proteins was evaluated in Western blotting. Two experiments with the same results were performed.
DISCUSSION
This study demonstrates a novel role for the Ca 2+ binding myeloid-related proteins S100A8 and S100A9 in myeloid cell diff erentiation. It suggests that up-regulation of these proteins in HPCs is primarily responsible for defective myeloid cell diff erentiation in cancer. S100A8 and S100A9 were previously implicated in traffi cking of granulocytes and monocytes, especially during infl ammation and metabolism of arachidonic acid ( 23 ) . Here, we show that up-regulation of these proteins results in inhibition of DC diff erentiation and accumulation of MDSCs. The STAT3 transcription factor upregulates the expression of S100A8 and S100A9 , which is consistent with the previous observation that diff erent tumor-derived factors mediate their immunosuppressive eff ects via hyperactivation of Jak2 -STAT3 signaling in myeloid cells ( 27 ) . Two of the cytokines (IL-10 and M-CSF) that were directly implicated in tumor-induced abnormalities of DCs ( 42, 43 ) were previously found to up-regulate S100A9 ( 44, 45 ) . Consistent with these results, a direct connection between > 30% of wild-type cells. Less than 10% of wild-type cells were F4/80 + Gr-1 Ϫ macrophages or CD11c + DCs. In sharp contrast, the majority of cells generated from gp91 Ϫ / Ϫ MDSCs were macrophages and DCs ( Fig. 7 C ) . These fi ndings suggest that ROS mediate the inhibitory eff ects of S100A9 on myeloid cell diff erentiation.
To further explore this premise, F1 mice were generated by crossing S100A9Tg and gp91 phox KO mice. As a control, we used the F1 cross of S100A9Tg mice with wild-type C57BL/6 mice. Mice that contained GFP-positive cells and exhibited suboptimal ROS production in response to PMA stimulation were selected for experiments. Lin Ϫ c-kit + progenitor cells were sorted and cultured with a cocktail of cytokines to generate myeloid cells. Progenitor cells from gp91 phox KO x S100A9Tg F1 mice produced signifi cantly more CD11c + DCs and signifi cantly less Gr-1 + CD11b + cells than did progenitors from C57BL/6 x S100A9Tg mice ( Fig. 7 D ) . Collectively, these diverse data suggest that S100A9 may suppress myeloid cell diff erentiation via persistent up-regulation of ROS in progenitor cells. Third, overexpression of S100A9 in myeloid cells of transgenic mice inhibited diff erentiation of macrophages and DCs and induced the accumulation of IMCs. Cells overexpressing S100A9 had a potent suppressive eff ect on T cell activity similar to that seen in tumor-associated MDSCs. Moreover, S100A9Tg mice were more susceptible to challenge with immunogenic tumors than wild-type mice. It is important to point out that this eff ect may not necessarily be caused entirely by accumulation of MDSCs or loss of DCs. Although our preliminary experiments indicate that T cells from S100A9Tg mice do not express S100A9 and exhibit normal function, we cannot yet exclude a possible contribution of lymphoid cells to immune suppression in this mouse model.
Use of the S100A9 expression vector containing the GFP reporter allowed us to isolate GFP-positive cells with S100A9 overexpression and to compare them to GFP-negative cells from the same mouse as an internal control to rule out contributions of systemic or microenvironment eff ects. Our data strongly suggest that S100A9 exerts its eff ect on myeloid cell diff erentiation via intracellular mechanisms rather than through extracellular secretion of protein. GFP Ϫ myeloid cells in S100A9Tg mice displayed a normal phenotype despite the fact that they were located in close proximity to GFP + cells that were dramatically aff ected. In addition, splenocytes from control and Tg mice secreted similar levels of S100A9, as well as S100A8. Finally, soluble factors from S100A9Tg splenocytes, as well as recombinant proteins, did not aff ect the diff erentiation of wild-type myeloid cells.
The molecular mechanism of S100A8/A9 eff ects on myeloid cell diff erentiation is currently not clear and requires further investigation. Several potential mechanisms could be explored.
These proteins may aff ect DC diff erentiation via their Ca 2+ binding activity or by inhibiting casein kinase I and II activity, which may be associated with myeloid cell maturation and function. Up-regulation of S100A9 may sensitize myeloid cells to the eff ects of tumor-derived factors. For instance, we have shown that overexpression of S100A9 results in up-regulation of c-kit on the surface of myeloid cells. Tumor-derived SCF, the c-kit ligand, has been implicated in the accumulation of MDSCs in cancer ( 52 ) . However, the fact that S100A8 overexpression induced up-regulation of c-kit, but did not aff ect production of Gr-1 + CD11b + cells argues against a c-kit -dependent mechanism. Recently, a novel role of S100A9 as an endogenous ligand for Toll-like receptor 4 (TLR4) was revealed ( 53 ) . We have previously demonstrated that MDSC expansion requires signaling through the downstream target TLR MyD88 ( 16 ) . It is possible that hyperactivation of TLR signaling may interfere with the normal process of myeloid cell diff erentiation, and S100A9 may be a major mediator of this eff ect.
Another possible mechanism by which S100A8/A9 might inhibit myeloid cell diff erentiation is linked to the ability of these proteins to facilitate ROS production by myeloid cells. S100A8/A9 is actively involved in the regulation of ROS generation by NAPDH oxidase ( 23 ) . Studies demonstrated STAT3 activity and S100A9 expression in breast cancer cells was recently reported ( 46 ) .
Several lines of evidence presented here support the conclusion that up-regulation of S100A9 causes inhibition of DC and macrophage diff erentiation and accumulation of MDSCs.
First, S100A9 was crucial for the in vivo increase in the number of MDSCs in response to inoculation of mice with tumor cells or CFA. S100A9 was also critical for the inhibitory eff ects of tumor-derived factors on myeloid cell diff erentiation in vitro . Our data showing normal myeloid cell diff erentiation in naive S100A9KO mice are consistent with previous studies in which abnormalities in myeloid cells of S100A9KO mice were not detected ( 32, 47 ) . Apparently, under physiological conditions, S100A9 is not essential for myeloid cell diff erentiation. However, in the pathological response to challenge with tumor-derived factors or infection, S100A9 is required for both hyperproduction of MDSCs and blockade of DC diff erentiation.
Second, overexpression of S100A9 in ES cells dramatically compromised their ability to diff erentiate into mature myeloid cells, particularly DCs and macrophages. The model of DC generation from ES cells has now been validated in several studies ( 33, 48, 49 ) , and it was chosen for our studies because precursors of granulocytes and monocytes normally express high levels of S100A9 ( 23 ) . Therefore, we hypothesized that if S100A9 is important for myeloid diff erentiation, it would most likely aff ect the diff erentiation of early progenitor cells. Our data, indeed, demonstrate that S100A9 overexpression blocks normal DC diff erentiation. This is consistent with the observation that mature DCs have very low or undetectable levels of this protein. Our results concur with those of Hashimoto et al., who performed serial analysis of gene expression in human DCs and found that, in contrast to monocytes, DCs did not express transcripts for S100A8 or S100A9 ( 50 ) . Apparently, to progress toward macrophage and DC diff erentiation, myeloid cells must down-regulate S100A9 expression. If such down-regulation is prevented, DC and macrophage diff erentiation is halted. Instead, ES cells overexpressing S100A8/A9 produced Gr-1 + cells and myeloid progenitors able to form myeloid colonies, which is reminiscent of the phenomenon observed in tumor-bearing mice ( 1 ). Because S100A8 and S100A9 form heterodimers, our initial hypothesis was that overexpression of both proteins would have a stronger eff ect on DC diff erentiation than would S100A9 alone. However, although double-transfected ES cells formed myeloid colonies more readily than did S100A9 single transfectants, they aff ected myeloid cell diff erentiation equally. This may suggest that up-regulation of S100A9 homodimers is suffi cient to block DC diff erentiation. In line with these fi ndings was the observation that the eff ect of S100A8 overexpression on DC diff erentiation was less pronounced than that of S100A9. In addition, S100A8 failed to induce the accumulation of Gr-1 + CD11b + cells. Although diff erent functions of S100A9 and S100A8 have been described in several experimental systems ( 51 ) , more studies are needed to clarify the mechanism of this phenomenon.
fer to remove red blood cells. Bone marrow cells were harvested from the femurs and tibias of mice and enriched for HPCs by depletion of lineagespecifi c cells, as previously described ( 55 ) . In brief, bone marrow cells were incubated with a mixture of antibodies (TIB-207, TIB-210, TIB-120, anti-TER-119, anti-Gr-1, and anti-B220) for 30 min on ice, washed, and treated with complement for 1 h at 37 ° C. Dead cells were then removed by centrifugation over a Lympholyte M gradient. The resulting fraction contained < 20% of lineage-positive cells as detected by fl ow cytometry. 500,000 enriched HPCs were placed into each well of 24-well plates in 2-ml of RPMI supplemented with 10% FBS, 20 ng/ml GM-CSF, and 10 ng/ml IL-4. This complete medium was replaced every 3 d, and cells were collected for further analysis at indicated time points. To assess the eff ects of tumor-derived factors on DC diff erentiation, HPCs were fed with complete medium supplemented with 25% medium conditioned for 48 h by subconfl uent cultures of NIH 3T3 fi broblasts as a control, or the C3, CT26, or EL4 tumor cell lines. For DC activation, 5 ng/ml TNF-␣ was added to RPMI complete medium for 48 h or 1 μ g/ml LPS for 24 h before cell analysis.
CTL assay. Splenocytes from EL4 tumor-bearing mice were cultured for 7 d with irradiated EL4 cells, in 10% FBS RPMI, supplemented with 20 ng/ml IL-15 and 20 ng/ml IL-21. On day 7, cytotoxicity was performed in a standard 6-h 51 Cr-release CTL assay. The target cells were EL-4 incubated in duplicates at a serials eff ector/target ratio.
Real-time qPCR. Total RNA was extracted from cells with Trizol (Invitrogen). Traces of DNA were removed by treatment with DNase I. The cDNA was synthesized from 1 μ g of total RNA using random hexamers and Superscript II reverse transcription (Invitrogen) according to the manufacturer ' s protocol. PCR was performed with 2.5 μ l cDNA, TaqMan Universal PCR Master Mix (Applied Biosystems), and target gene assay mix containing sequence-specifi c primers for S100A8 or S100A9 and 6-carboxyfl uorescein (6-FAM) dye-labeled TaqMan minor groove binder (MGB) probe (Applied Biosystems). Amplifi cation with 18S endogenous control assay mix was used for controls. Data quantitation was performed using the relative standard curve method. Expression levels of the genes were normalized by 18S rRNA.
RT-PCR and Southern blots. Total RNA was extracted from cells with Trizol. Traces of DNA were removed by treatment with DNase I. The cDNA was synthesized from 1 μ g of total RNA using random hexamers and Superscript II reverse transcription according to the manufacturer ' s protocol. Samples were subjected to initial denaturation at 94 ° C for 3 min and 24 cycles (for S100A8 and S100A9 ) or 28 cycles (for hprt ) of PCR (94 ° C for 30 s, 54 ° C for 30 s, and 72 ° C for 45 s) with fi nal extension for 7 min at 72 ° C. The number of cycles was selected after preliminary experiments to avoid saturation of the PCR products. PCR primer pairs used in this study include the following: S100A8 forward for HPC and DC cultures: 5 Ј -ACAATGCCGTCT-GAACTGG; reverse, 5 Ј -CTCTGCTACTCCTTGTGGCTGTCT-3 Ј , or S100A8 forward for ES transfectants, 5 Ј -GGAAATCACCATGCCCTC-TACAA-3 Ј ; reverse, 5 Ј -ATGCCACACCCACTTTTATCACC-3 Ј . S100A9 forward for HPC and DC cultures, 5 Ј -GGAGCGCAGCATAACCAC-3 Ј ; reverse, 5 Ј -GCCATTGAGTAAGCCATTCC-3 Ј , or S100A9 forward for ES transfectants, 5 Ј -CATCGACACCTTCAATCAATACTC-3 Ј ; reverse, 5 Ј -GCCATCAGCATCATACACTCCTC-3 Ј . hprt : forward, 5 Ј -GATT-CAACTTGCGCTCATCTTAGGC-3 Ј ; reverse, 5 Ј -GTTGGATACAG-GCCAGACTTTGTTG-3 Ј . The PCR products were separated on 1% agarose gels. The sizes of PCR products were: 279 bp for S100A8 in HPC and DCs and 174 bp for ES transfectants; 378 bp for S100A9 in HPC and DC cultures and 206 bp for ES transfectants; and 164 bp for hprt. PCR products were transferred in an alkaline buff er (0.4 N NaOH, 1 M NaCl) onto Hybond N + nylon transfer membranes (GE Healthcare), and probed with 32 P-labeled oligonucleotide probes: S100A8 , 5 Ј -GGAGTTCCTTGCGAT-GGTGATA-3 Ј ; S100A9 , 5 Ј -ACATCATGGAGGACCTGGACACA-3 Ј ; hprt , 5 Ј -GTTGTTGGATATGCCTTGAC-3 Ј .
Western blot analyses were performed as previously described ( 27 ) .
that S100A8 and S100A9 directly bind to p67 phox and p47 phox , critical components of the NADPH complex ( 38, 39 ) . This binding potentiates NADPH oxidase activation in neutrophils. Furthermore, S100A9 inhibits the expression of a substantial number of genes in myeloid cells, including gp91 phox ( 50 ) , suggesting that diff erences in ROS production in the absence of S100A9 may refl ect a general role of this protein during myeloid diff erentiation. ROS, in turn, are the major factors inhibiting diff erentiation of DCs in tumor-bearing mice ( 29 ) . Our data ROS play an important role in S100A9-mediated eff ects on myeloid cell diff erentiation. In recent years, it has become increasingly evident that infl ammation plays a critical role in tumor progression ( 54 ) . This study not only demonstrates a novel molecular mechanism responsible for the suppression of immune responses in cancer via accumulation of MDSCs but also provides a potential direct molecular link between immune suppression, MDSCs, and proinfl ammatory factors. Together with present and previous observations that lack of S100A9 or STAT3 function promotes tumor rejection via immunological mechanisms ( 31 ), these cumulative fi ndings reveal a pathway that negatively regulates the immune response in cancer.
MATERIALS AND METHODS
Reagents.
The following antibody-producing hybridomas were purchased from the American Type Culture Collection (ATCC) and used as supernatants: anti-CD4 (L3T4, TIB-207), anti-CD8 (Lyt-2.2, TIB-210), and anti-MHC II (TIB-120). Anti-IA b , IAd/IEd, Gr-1, CD4, CD8, CD11b, CD86 (B7-2), CD45, CD11c, CD34, Sca-1, c-Kit, isotype control antibodies, and mouse cell lineage depletion kit were obtained from BD Biosciences. Anti-CD3 and antiTer-119 antibodies were obtained from BioLegend, anti-F4/80 antibody from Serotec, streptavidin microbeads and mouse lineage cell depletion kit from Miltenyi Biotec, anti -mouse S100A8, and anti-S100A9 from Santa Cruz Biotechnology. For immunohistochemical staining, anti-S100A9, anti -goat, antirat conjugated with biotin antibodies, and Vectastain ABC kit were purchased from Vector Laboratories. Myeloid Long-Term Culture Medium for Primitive Mouse Hematopoietic Cells (MyeloCult media) and hydrocortisone were purchased from StemCell Technologies. Low-Tox rabbit complement and Lympholyte M were obtained from Cedarlane Laboratories. Recombinant murine GM-CSF, IL-4, TNF-␣ , IL-3, IL-11, Flt3L, and SCF were obtained from R & D Systems. LPS was obtained from Sigma-Aldrich. For depletion of CD8 + cells anti-CD8 Lyt 2.2 antibody (ATCC) were generated as ascitis (provided by E. Celis, H. Lee Moffi tt Cancer Center, Tampa, FL). Recombinant S100A9 and A8 proteins were previously described ( 53 ) . AVN mammary carcinoma cell line was provided by K. Knutson (Mayo Clinic, Rochester, MN).
Animals. 6 -8-wk-old female BALB/c and C57BL/6 mice were purchased from Harlan. FVB/N mice were purchased from Charles River Laboratories. The gp91 phox KO and OT-1 mice were obtained from The Jackson Laboratory. S100A9-defi cient mice were previously described ( 32 ) and housed in pathogen-free units of the Division of Comparative Medicine vivarium at H. Lee Moffi tt Cancer Center, University of South Florida. These mice were backcrossed for six generations to C57BL/6 mice. Control groups included mice with wild-type genotype (S100A9 +/+ ) from the same generation of backcross.
All animal experiments were approved by the Institutional Animal Care and Use Committee and performed in accordance with U.S. Public Health Service policy and National Research Council guidelines.
Preparation of cells. Spleens were collected from control or tumor-bearing mice. Single-cell suspensions of splenocytes were treated with ACK buf-promoter at the NotI site of pH2K-i-LTR that had been previously modifi ed to convert a 5 Ј EcoRI site to SalI (provided by P. Persons, St. Jude Children's Hospital, Memphis, TN). After verifi cation of construct orientation and sequence, the 5.15-kb H2K-S100A9-IRES-GFP transgene was isolated by SalI digestion and electroelution from 1% agarose gel, followed by ethanol precipitation. To generate H2K-S100A9 transgenic mice, the Moffi tt Mouse Models Core facility microinjected the purifi ed DNA at 3 ng/ μ l into pronuclei of 0.5 dpc fertilized zygotes from the FVB/N strain and implanted surviving embryos into the oviducts of pseudopregnant CD1 foster recipients per standard procedures. Transgenic founders and their off spring were genotyped by slot-blot hybridization of tail DNA to a radiolabeled GFP probe.
Generation of myeloid cells from sorted HPCs in transgenic mice.
Bone marrow cells obtained from wild-type or S100A9Tg mice were depleted of lineage-positive cells using mouse lineage cell depletion kit (Miltenyi Biotec), and stained with the following antibodies: pacifi c blue -conjugated CD3; Percp-conjugated CD4, CD8, Ter-119, CD11b, Gr-1, and B220; and APC-conjugated c-kit. Lin Ϫ c-Kit + GFP + and Lin Ϫ c-Kit + GFP Ϫ stem cells were sorted using a FACSAria. To diff erentiate myeloid progenitor cells, 35,000 Lin Ϫ c-Kit + GFP + or Lin Ϫ c-Kit + GFP Ϫ cells were placed in each well of 24-well plates and cultured for 5 d in Myeloid Long-Term Culture Medium for Primitive Mouse Hematopoietic Cells, supplemented with 20 ng/ml of IL-3, IL-11, SCF, Flt3L and GM-CSF. 500,000 cells were cultured in RPMI supplemented with 10% FBS and 20 ng/ml of GM-CSF for another 7 d. 24 h before cell analysis, 1 μ g/ml LPS was added to activate DCs.
Isolation of Gr-1 + cells. Gr-1 + cell isolation was performed using Mini-MACS microbeads according to the manufacturer ' s protocol (Miltenyi Biotec). The purity of Gr-1 + cells was consistently > 95% in all samples. The depletion of Gr-1 + cell was achieved by two rounds of isolation using magnetic beads. Negative fractions were collected and used as Gr-1 Ϫ cells. They contained < 5% Gr-1 + cells. In some experiments, Gr-1 + CD11b + cells were sorted using FACSAria cell sorter (BD Biosciences).
IFN-␥ ELISPOT assay.
MDSCs were isolated from spleens of wild-type and S100A9Tg mice using cell sorting on FACSAria cell sorter. The purity of cell populations was > 99%. As responder cells, we used splenocytes from FVB/N mice immunized twice with s.c. injection of 5 × 10 5 DCs loaded with MHC class I (H2-D q ) restricted rat HER-2/ neu -derived peptide PD-SLRDLSVF. MDSCs were mixed with splenocytes at 1:3 and 1:6 ratios. The number of IFN-␥ -producing cells in response to stimulation with the specifi c (PDSLRDLSVF) or control (RAHYNIVTF) peptides (10 μ g/ml) was evaluated in a 42-h ELISPOT assay performed as previously described ( 57 ) . The numbers of spots were counted in triplicates and calculated using an automatic ELISPOT counter (Cellular Technology, Ltd).
Allogeneic mixed leukocyte reaction. T cells were isolated from naive FVB/N mice using a T cell enrichment column (R & D Systems), and 10 5 cells were placed in each well of round-bottomed 96-well plates. DCs were generated from BALB/c mice using GM-CSF and IL-4. DCs were mixed with T cells at a 1:50 ratio. MDSCs isolated from wild-type and S100A9Tg mice were added to cultures at diff erent MDSC/T cells ratios (from 1:2 to 1:16). Cell proliferation was evaluated in triplicates after a 96-h incubation using 3 [H]thymidine incorporation.
Measurement of ROS.
ROS was measured by labeling cells either with the oxidation-sensitive dye DCFDA ( 28 ) for experiments with S100A9 KO mice and ES cells or hydroethidine ( 58 ) for experiments with S100A9 Tg mice.
Hematoxylin-eosin and immunohistochemical staining of tumor tissues. EL4 tumor tissues were either fi xed in paraformaldehyde or frozen with OCT. Hematoxylin-eosin staining was performed on paraffi n embedding tissues. 5-μ m-thick sections were stained with hematoxylin-eosin and examined under light microscopy. Immunohistochemical staining was Chromatin immunoprecipitation assay (ChIP). 32D cells were cultured in 10% FBS RPMI 1640 supplemented with IL3. Preparation of chromatin-DNA and ChIP assay were performed with kit (Millipore) per the manufacturer ' s instructions, using antibodies against STAT3 (Cell Signaling Technology), normal rabbit IgG (Santa Cruz Biotechnology), and protein A agarose/salmon sperm DNA (Millipore). Sonication was performed using a Branson Sonifi er (model 450; VWR Scientifi c). After reversal of cross-linking, purifi ed DNA was subjected to PCR with the following primers spanning the potential STAT3 binding site in the S100A9 promoter: forward 5 Ј -ACTTCTGGAAATCAGTCTGGC-GGT-3 Ј ; reverse, 5 Ј -T GGGTTCTTTCCAGCTTCTGGCTA-3 Ј . Primers for S100A8 promoter: forward, 5 Ј -ACACCTCGTACAACTGGAACC-ACA-3 Ј ; reverse, 5 Ј -TCAGCATC A TCCAAGAGAGCCCAA-3 Ј . Primers for ␤ -actin: forward, 5 Ј -T A G G G T G TAGACTCTTTGCAGCCA-3 Ј ; reverse, 5 Ј -A G C G T C T G GTTCCCAATACTGTGT-3 Ј .
Experiments with ES cells. S100A1 , S100A8 , and S100A9 were amplifi ed from mRNA of HPC cells isolated from BALB/c bone marrow using RT-PCR. The pairs of primers were as follows: for S100A1 forward, 5 Ј -GCTCGAGGCCACCATGGGCTCTGAG-3 Ј containing XhoI site; reverse, 5 Ј -AGAATTCGTGCTCAACTGGTCTCCCA-3 Ј ; containing EcoRI site; S100A8 forward, 5 Ј -CTCGAGCCACCATGCCGTCTG A-ACTG-3 Ј , containing XhoI site at the 5 Ј end and modifi ed Kozak sequence; reverse, 5 Ј -CAGGAATTCAGCCCTAGGCCAGAAG-3 Ј , containing EcoRI site at 5 Ј end; S100A9 forward, 5 Ј -AGATATCAGATCTGCCACCATG-GCCAACAAAGCA-3 Ј , containing EcoRV and BglII sites at 5 Ј end and modifi ed Kozak sequence; reverse, 5 Ј -AGTCTCGAGGCTGACCTCT-TAATTA-3 Ј , containing XhoI site at 5 Ј end. For S100A8, the amplifi ed 311-bp fragment was digested using XhoI and EcoRI, and subsequently inserted into pcDNA3.1(-). For S100A9, the amplifi ed 375-bp fragment was digested using EcoRV and XhoI, and inserted into pcDNA3.1(+). S100A1 fragment was cloned into pcDNA3.1(-). The vectors were verifi ed by sequencing. To create cell lines expressing both S100A8 and S100A9, the latter gene was recloned using EcoRV and XhoI into pcDNA3-Hygro. R1 ES cells were transfected with Lipofectamine (Invitrogen) mixed with empty pcDNA3.1 vector; pcDNA3.1 containing S100A1, S100A9, or both S100A8 and S100A9 (S100A8/9); or the STAT3c plasmid (R1-Stat3C, ( 56 ) or its vector control RcCMV-Neo (R1-C). ES cells were grown in knockout DMEM containing 2 mM l-glutamine, 0.1 mM nonessential amino acids, 100 μ M 2-mercaptoethenol, 15% ES cell certifi ed FBS (Invitrogen), 1,000 U/ml LIF (ESGRO; Chemicon International, Inc.), and 200 μ g/ml G418 or both G418 and 100 μ g/ml hygromycin. DC diff erentiation from S100A9-overexpressing ES cells. Diff erentiation of DCs from ES cells was performed as previously described ( 33 ) . In brief, ES cells were grown on gelatinized plates in complete knockout DMEM, as described above. To induce formation of embryoid bodies, ES cells were transferred to bacterial-grade Petri dishes in medium without LIF and cultured for 14 d; they were fed every other day. On day 14, 1 EB was transferred to each well of a 24-well plate and incubated for 30 d in 2 ml/ well RPMI medium containing 15% FBS, 20 ng/ml GM-CSF, and 10 ng/ml IL-3. Half of the medium was changed every 3 d. 5 ng/ml TNF-␣ was added for the last 5 d before analysis.
Assessment of colony formation. Colony formation by cells derived from in vitro diff erentiation was measured using semisolid 1% methylcellulose medium supplemented with recombinant cytokines supporting the optimal growth of myeloid colonies (MethoCult M3534; Stem Cell Technologies). Cells generated from ES cells on day 35 were collected and seeded at 25,000 cells/well in 6-well plates. Colonies were scored on day 10. S100A9 transgenic mice. The 375-bp BglII -XhoI S100A9 fragment from pcDNA-S100A9 was inserted into pMIGR1 upstream of an IRES-GFP. A 1.65-kb BglII -SalI fragment containing S100A9-IRES-GFP was end-fi lled and ligated to NotI linkers and cloned downstream of the H2K Down-regulation of Stat3 by siRNA in 32D cells. 32D cells (10 6 ) were mixed with 100 nM Stat3 siRNA (Dharmacon) in 100 μ l 32D nucleofector solution, and transfection was performed using Nucleofector I (Amaxa). As a control, nontargeting siRNA pool was used (siGenome). The gene expression was evaluated 36 h later using qRT-PCR, and protein levels were measured after 72 h by Western blotting.
Statistics. Statistical analysis was performed using parametric and nonparametric methods on JMP software (SAS Institute). In all cases, P values were calculated using two-sided t test.
Online supplemental material. Fig. S1 shows the expression of S100A9 and A8 in myeloid cells in tumor-bearing mice. Fig. S2 demonstrates that tumor cell-conditioned medium inhibits diff erentiation of DCs and induces accumulation of MDSCs in vitro. Fig. S3 shows that diff erentiation of myeloid cells in S100A9-defi cient naive mice is not impaired. Fig. S4 shows that C3 tumor is rejected by most of S100A9 KO mice. Fig. S5 provides the analysis of cytotoxicity by T cells from S100A9 KO mice. Fig. S6 shows the immunohistochemical evaluation of tumors from S100A9 KO mice. Fig. S7 demonstrates the expression of S100A9 and A8 in transfected ES cells. Fig. S8 shows the phenotype of myeloid cell colonies in cells transfected with S100A9/A8. Fig. S9 shows the colony formation by spleen and bone marrow cells from S100A9Tg mice. The online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20080132/DC1.
